Macugen is a drug owned by Bausch And Lomb Inc. It is protected by 5 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Jan 04, 2017. Details of Macugen's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US6011020 | Nucleic acid ligand complexes |
Jan, 2017
(7 years ago) |
Expired
|
| US5932462 | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
Aug, 2016
(8 years ago) |
Expired
|
| US6051698 | Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes |
May, 2015
(9 years ago) |
Expired
|
| US6113906 | Water-soluble non-antigenic polymer linkable to biologically active material |
Oct, 2013
(11 years ago) |
Expired
|
| US5919455 | Non-antigenic branched polymer conjugates |
Oct, 2013
(11 years ago) |
Expired
|
While patent expiration is one way of estimating the generic date of a drug, if a patent gets invalidated somehow, the generic of the drug may arrive early. Being aware of all relevant patents can help in avoiding legal pitfalls. Given below are details of the litigation history of Macugen and ongoing litigations to help you estimate the early arrival of Macugen generic.
Macugen's Litigations
Macugen been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Oct 05, 2006, against patent number US6113906. The petitioner , challenged the validity of this patent, with RICHARD B. GREENWALD et al as the respondent. Click below to track the latest information on how companies are challenging Macugen's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US6113906 | October, 2006 |
Decision
(05 Oct, 2006) | RICHARD B. GREENWALD et al | |
US patents provide insights into the exclusivity only within the United States, but Macugen is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Macugen's family patents as well as insights into ongoing legal events on those patents.
Macugen's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Macugen's generic launch date based on the expiry of its last outstanding patent is estimated to be Jan 04, 2017 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Macugen Generics:
There are no approved generic versions for Macugen as of now.
About Macugen
Macugen is a drug owned by Bausch And Lomb Inc. It is used for treating VEGF-mediated ocular diseases. Macugen uses Pegaptanib Sodium as an active ingredient. Macugen was launched by Bausch And Lomb Inc in 2004.
Approval Date:
Macugen was approved by FDA for market use on 17 December, 2004.
Active Ingredient:
Macugen uses Pegaptanib Sodium as the active ingredient. Check out other Drugs and Companies using Pegaptanib Sodium ingredient
Treatment:
Macugen is used for treating VEGF-mediated ocular diseases.
Dosage:
Macugen is available in injectable form for intravitreal use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| EQ 0.3MG ACID/0.09ML | INJECTABLE | Discontinued | INTRAVITREAL |